Dmitry Balyasny’s Orchestra BioMed OBIO Stock Holding History

Dmitry Balyasny’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,268	Closed	-$75.8K	–	3334
2025 Q4	$75.8K	Buy	+18,268	New	+$73.7K	﹤0.01%	2985

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Dmitry Balyasny's OBIO Position: Q1 2026 in Review

Dmitry Balyasny sold out of Orchestra BioMed (OBIO) in Q1 2026, closing a stake of 18,268 shares — an estimated $75.8K sold.

Dmitry Balyasny first reported a position in OBIO in Q4 2025 and held it in 1 quarter. The position peaked at $75.8K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

Dmitry Balyasny reported no remaining Orchestra BioMed position as of Q1 2026 after selling out during the quarter.
Dmitry Balyasny sold 18,268 Orchestra BioMed shares in Q1 2026, an estimated $75.8K.
Dmitry Balyasny first reported a position in Orchestra BioMed in Q4 2025 and held it in 1 quarter.
Dmitry Balyasny's Orchestra BioMed position peaked at $75.8K in Q4 2025.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.